SEPTEMBER SPECIAL - FREE SHIPPING TO THE USA
Menu
Comprehensive Compilation of Research Studies on Amorphous Minerals (ACC), the Main Ingredient in PH Gastrilex, Developed by ‘Amorphical’ and Sold by IGC Worldwide
Discover the extensive array of research studies on our amorphous mineral products, originally developed by Amorphical. This collection spans recent years and includes groundbreaking findings on the enhanced absorption rates of amorphous calcium carbonate. The research covers a wide range of applications, from studies on cancer cells and space environments to COVID-19, in vitro fertilization, and beyond. Through our partnership with Amorphical, IGC is proud to bring these innovative health solutions to the global market.
Publication Date: November 26, 2023 | Last Updated: January 11, 2024 | Estimated Reading Time: 4 minutes
This page features a comprehensive list of studies that have been accepted for publication in scientific journals.
COVID-19 Research (2022)
Remarkable outcomes have been documented in a renowned scientific journal (ClinicalTrial), summarizing a clinical trial conducted by the company with patients affected by COVID-19. The findings are definitive: patients experienced swift recovery and there was a significant prevention of clinical deterioration, reducing the necessity for intensive care admissions and the risk of mortality. The trial aimed to evaluate the safety and efficacy of administering amorphous calcium carbonate (ACC) in various formulations. The investigational drug was named Amor18 and was assessed as a potential treatment for hospitalized COVID-19 patients with moderate to severe symptoms. Amor18 was administered using a dual approach of sublingual powder and inhalation therapy. The results were promising: all patients receiving Amor18’s amorphous calcium carbonate formulation recovered and were subsequently discharged within days. None of the patients treated with amorphous calcium carbonate required intensive care or succumbed to the illness.
This is in stark contrast to a control group of 30 patients who were administered a placebo, among whom 7 required intensive care and 3 passed away
August 2023: Breakthrough in In Vitro Fertilization (IVF) Research with Amorphous Calcium Carbonate (ACC)
Significant advancements in embryo development have been achieved through the use of amorphous calcium carbonate (ACC). Amorphical, in collaboration with leading scientists in the field of fertilization, has conducted extensive research over the past seven years. The compelling findings from these studies have been recently published in the acclaimed American scientific journal JARG. The editor highlighted the work of Professor Amir Arab, who led the research efforts, with an enthusiastic remark: “The results are exciting!” The publication details rigorous experimentation on over 2,200 embryos cultivated in various growth mediums provided by top industry companies. By integrating ACC into these commercial media, researchers observed notable enhancements in the embryos’ growth rate, quality, and the proportion reaching the crucial developmental stage of hatched blastocysts ready for uterine implantation.
These findings suggest a promising increase in IVF success rates, leading to more successful pregnancies. Consequently, this could reduce the emotional and physical toll on prospective mothers and result in significant healthcare cost savings related to treatments and hospital stays.
Cancer Research Insights (July 2023)
Amorphical has dedicated the last eight years to conducting an extensive series of pre-clinical and in vitro studies targeting various cancer types. These studies have been undertaken in Amorphical’s own laboratories as well as through partnerships with leading research institutions and hospitals in Israel and internationally. The promising outcomes of these research efforts have culminated in a scholarly article that has been accepted for publication in the forthcoming journal “Cancers” by MDPI. This particular study focuses on lung cancer and substantiates the efficacy of amorphous nano-minerals in its treatment. Detailed within the article is a series of experiments involving lung cancer cells, both murine and human, that were engrafted into mice. The treatment groups receiving amorphous calcium carbonate showcased significant results compared to the control groups.
For a comprehensive understanding, the full article is accessible via the following link:
Adobe Acrobat Link to Cancer Research Article.
Pioneering Research Indicates Performance Enhancement in Female Athletes (January 2023)
A groundbreaking study conducted by Tel Hai College has revealed performance enhancements among female athletes, tracing back to a novel development by the Israeli firm Amorphical. The collaborative effort involved the Olympic team’s dietitian, a physiologist from Tel Hai University, and Jordan Ovadia, a student from the Faculty of Nutritional Sciences at Tel Hai College. Over a period of nine weeks, they engaged in a controlled investigation with female gym-goers, which included a placebo group for comparison. The results were decisive, showing a marked improvement in the group of female athletes who incorporated pH Sport into their regimen.
For detailed insights, the full article can be accessed here: MDPI Link to Research on Female Athletes’ Performance.
2011 Study Highlights Nanotechnology’s Role in Boosting Calcium Absorption
Researchers from Ben-Gurion University of the Negev (BGU) have pioneered a groundbreaking technology that enhances the stabilization of amorphous calcium carbonate (ACC). This stabilized ACC is demonstrated to be significantly more biologically absorbable and retainable than other forms of calcium currently utilized in dietary supplements. This innovation was featured in the scientific outlets “Nanotech Now” and “Science Daily.”
The inspiration for this technology comes from freshwater crustaceans, which efficiently stabilize this form of mineral to effectively store and rapidly mobilize calcium when needed. Emulating the crustaceans’ natural mechanism, BGU’s team assessed the synthetic ACC’s efficacy against conventional calcium supplements through animal testing. The findings revealed that the synthetic ACC compound led to absorption and retention rates that were up to 40 percent higher in the bloodstream and 30 percent greater in bone density compared to other calcium sources. Such marked enhancement in calcium uptake could potentially lower the necessary dosage of supplements, diminish adverse effects, and improve patient adherence.
For an in-depth review, the full article is available at: ScienceDaily Link to Calcium Absorption Article.
Clinical Study Confirms: Amorphous Calcium Carbonate (ACC) Exhibits Double the Absorption Rate of Crystalline Calcium Carbonate (CCC)
A meticulously designed double-blind, randomized, cross-over study has established the superior bioavailability of the amorphous calcium supplement DENSITY compared to traditional crystalline calcium carbonate (CCC). The research focused on 15 menopausal women, selected based on their lack of significant medical conditions and sufficient vitamin D levels. The study utilized the Dual Stable Isotope technique, a state-of-the-art scientific method that tracks the supplements’ calcium isotopes for maximum precision within the participants’ bodies.
Key findings revealed that amorphous calcium’s absorption in the intestine is twice as efficient as that of CCC when ingested post-meal. Additionally, a notable case within the study showed an increase in intestinal calcium absorption by 4.6 times after the administration of amorphous calcium on an empty stomach, in contrast to CCC.
For detailed information, the full article can be accessed at: Link to Clinical Research on ACC Absorption.
Upcoming Publications to Watch For:
Research involving amorphous calcium carbonate conducted in the unique environment of space will be detailed in forthcoming articles. Stay tuned for these exciting studies that extend the frontiers of science beyond Earth.
If you are a new customer, your satisfaction and positive results are our top priority.
This is why we recommend starting with three packages for your initial trial. Typically, you can expect to notice improvements within 3 to 4 weeks of regular use.
Should the product not meet your expectations or fail to deliver results, we offer a money-back guarantee on each unopened package
